Literature DB >> 26976421

Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer.

Alan Pollack1, Matthew C Abramowitz2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26976421     DOI： 10.1200/JCO.2015.66.2320

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer.

Authors:  Natsuo Tomita; Norihito Soga; Yuji Ogura; Jun Furusawa; Hidetoshi Shimizu; Sou Adachi; Hiroshi Tanaka; Daiki Kato; Yutaro Koide; Chiyoko Makita; Hiroyuki Tachibana; Takeshi Kodaira
Journal:  Br J Radiol       Date:  2017-12-05       Impact factor: 3.039

2.  High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes.

Authors:  Natsuo Tomita; Norihito Soga; Yuji Ogura; Norio Hayashi; Takumi Kageyama; Makoto Ito; Yutaro Koide; Maiko Yoshida; Kana Kimura; Chiyoko Makita; Hiroyuki Tachibana; Takeshi Kodaira
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-02       Impact factor: 4.553

3.  Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy.

Authors:  Alan Pollack; Felix M Chinea; Elizabeth Bossart; Deukwoo Kwon; Matthew C Abramowitz; Charles Lynne; Merce Jorda; Brian Marples; Vivek N Patel; Xiaodong Wu; Isildinha Reis; Matthew T Studenski; Javier Casillas; Radka Stoyanova
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-02-19       Impact factor: 7.038

4.  DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity.

Authors:  Nicolas Malaquin; Arthur Vancayseele; Sophie Gilbert; Laureen Antenor-Habazac; Marc-Alexandre Olivier; Zakia Ait Ali Brahem; Fred Saad; Guila Delouya; Francis Rodier
Journal:  Cells       Date:  2020-07-01       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.